Australian Pharma Stock News

If you are wondering whether Macquarie Group at around A$232 per share offers value or requires paying up for quality, this article breaks down what the current price really implies. The stock has seen mixed short-term moves, with a 3.2% decline over the last 7 days, but returns of 12.8% over 30 days, 14.0% year to date and 24.5% over 1 year, alongside 41.4% over 3 years and 72.8% over 5 years. Recent coverage has focused on Macquarie Group as one of the major Australian financials, with...

Whilst it may not be a huge deal, we thought it was good to see that the Stavely Minerals Limited ( ASX:SVY...

Codan Limited ( ASX:CDA ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...

Earlier this week, Commonwealth Bank of Australia confirmed it will cut 119 roles across Australia, including 43 at Bankwest, with some positions made redundant as processes are automated and lending functions reshaped. The move highlights how CBA is reallocating people and skills toward technology-enabled services, underscoring the operational shifts behind its evolving customer proposition. We'll now examine how these job cuts and automation efforts may influence Commonwealth Bank of...

Pantoro Gold has entered a funding and processing agreement with Mega Resources and Bain Global Resources. The deal provides up to A$20 million to advance stage two mining and development at the Rama Open Pit in Western Australia's Forrestania region. The partnership includes access to underground mining opportunities below the Rama Open Pit under a profit sharing arrangement. The move expands Pantoro Gold's production portfolio beyond its Norseman operations. Pantoro Gold (ASX:PNR) is...

Investors may be wondering whether Perseus Mining is reasonably priced at today's levels, or if the strong run has already accounted for much of the potential upside. The stock last closed at A$5.56, with returns of 10.8% over 30 days and 70.9% over 1 year, while the year to date return is a 1.4% decline. Recent news coverage has focused on Perseus Mining in the context of the gold sector and broader materials stocks, with investors weighing how gold producers fit into diversified...

Lynas Rare Earths (ASX:LYC) has moved into focus after achieving first commercial production of separated heavy rare earth oxides outside China, securing long term supply agreements, and receiving a 10 year Malaysian processing approval. See our latest analysis for Lynas Rare Earths. Despite a softer patch in recent weeks, with a 7 day share price return of an 11.98% decline and a 30 day share price return of a 9.04% decline, Lynas shares at A$18.22 still sit on a 49.10% year to date share...

If you are wondering whether Alkane Resources at around A$1.60 is still offering value or has already priced in the story, you are asking the right question. The share price has had a mixed short term pattern, with an 11.6% decline over 7 days, an 8.8% gain over 30 days, and returns of 15.9% year to date and 113.3% over the past year. These moves sit against a backdrop of ongoing attention on rare earths and gold producers. Funding, project timelines, and permitting updates often influence...

GenusPlus Group recently announced it had secured an A$110 million lump-sum, turnkey contract to deliver engineering, procurement, construction and commissioning for the 200 MW/800 MWh Koolunga Battery Energy Storage System project in South Australia, with work underway and completion targeted by September 2027. This contract materially expands GenusPlus Group’s presence in battery energy storage infrastructure, reinforcing its role in Australia’s ongoing grid and renewable energy...

Treasury Wine Estates (ASX:TWE) has drawn fresh investor attention after announcing a shift to a regional operating model, along with senior management changes, following a share price jump of more than 16%. See our latest analysis for Treasury Wine Estates. The recent move to a regional operating model and the Convida brand launch have arrived after a challenging period, with the 1 year total shareholder return of 47.59% decline contrasting with the 27.12% 30 day share price return. This...

Clinuvel Pharmaceuticals recently reported that the European Medicines Agency issued final scientific advice on its planned pivotal Phase III CUV107 trial, outlining how SCENESSE (afamelanotide) will be evaluated as a systemic treatment for non-segmental vitiligo in adults and adolescents. The regulator’s “totality of evidence” approach, with T-VASI50 as the primary endpoint and strong emphasis on patient-reported and photographic outcomes, underscores both the complexity and patient-centric...

Elevra Lithium (ASX:ELV) is back in focus after its March quarterly update highlighted improved execution at the North American Lithium operation, high plant utilization, stronger lithium recovery and record quarterly revenue of $81 million. See our latest analysis for Elevra Lithium. The share price has reacted strongly to the March update and the upcoming Q3 2026 results. A 1 month share price return of 52.02% has helped lift the 1 year total shareholder return to 322.46%, although the 3...

Adisyn follow on equity offering puts capital structure in focus Adisyn (ASX:AI1) has filed a follow on equity offering of A$14 million, issuing 207,407,407 ordinary shares at A$0.0675 each, a A$0.00405 discount per security via subsequent direct listing. See our latest analysis for Adisyn. The follow on offering comes after a period of sharp share price momentum, with Adisyn’s 30 day share price return of 300% and 1 year total shareholder return of 300% suggesting sentiment has recently...

Fortescue shares after recent performance Fortescue (ASX:FMG) has come under pressure recently, with the share price showing a 5.7% decline over the past day and a 6.8% decline over the past week, catching the attention of investors. See our latest analysis for Fortescue. At the current share price of A$19.78, the recent 5.7% 1 day and 6.8% 7 day share price declines extend a weaker short term trend, even though the 1 year total shareholder return of 35.5% remains firmly positive. This mix of...

Cochlear (ASX:COH) is back in focus after the company cut its fiscal year profit guidance, citing softer demand in the US, surgical capacity constraints in Western Europe, and external risks in China and the Middle East. See our latest analysis for Cochlear. The steep guidance cut has been met with a sharp reset in sentiment, with a 7 day share price return of 42.21% decline and a 1 year total shareholder return of 62.47% decline pointing to fading momentum, even as management reiterates its...

Scentre Group has recently reported its Q1 2026 operating results and moved to refinance its balance sheet, including issuing $750 million in senior variable rate notes due 2032 and launching a cash tender offer for subordinated notes due 2080. By retiring long-dated subordinated debt and replacing it with new senior variable-rate funding, the Group is actively reshaping its debt profile and interest cost mix, which may influence perceptions of its financial flexibility and risk. We’ll now...

The analysts covering 29Metals Limited ( ASX:29M ) delivered a dose of negativity to shareholders today, by making a...

Intelligent Monitoring Group Limited ( ASX:IMB ) is possibly approaching a major achievement in its business, so we...

If you are wondering whether Woolworths Group at A$37.89 is offering good value or just pricing in a lot of optimism, you are not alone. The stock has returned 3.0% over the last week, 4.2% over the past month, 28.7% year to date and 23.6% over the last year, which naturally raises questions about what is already baked into the current price. Recent coverage has focused on Woolworths Group as a core consumer staples name on the ASX, with attention on how shoppers are responding to pricing,...

While Eagers Automotive Limited ( ASX:APE ) might not have the largest market cap around , it saw a double-digit share...

Commonwealth Bank of Australia is cutting 119 jobs, including roles at its Bankwest subsidiary. The roles include positions linked to automation projects, pointing to changes in how the bank structures its operations. The move affects staff and workflows across parts of the group’s banking operations. For investors tracking ASX:CBA, these job cuts come against a backdrop of multi year share price performance, with the stock currently at A$174.49 and returns of 94.6% over 3 years and 135.1%...

National Australia Bank recently disclosed that first-half credit impairment costs are expected to reach about A$706 million, roughly double prior levels, while also revising its software capitalisation policy so more technology spending will be expensed from the second half of 2026. To reinforce its capital position amid heightened global uncertainty surrounding the Iran war, NAB is offering a discounted, partially underwritten dividend reinvestment plan that could raise up to...

Alkane Resources (ASX:ALK) reports record quarterly gold equivalent production. The company generates strong operating cash flow in the same quarter. Alkane Resources is added to the S&P/ASX 200 Index, lifting its market profile. Alkane Resources, a gold producer listed on the ASX under the ticker ASX:ALK, has released an update that combines record quarterly output with solid cash generation. The company is now also included in the S&P/ASX 200 Index, which brings it into a broader group of...

With inflation pressures, higher energy costs and uncertain rate paths shaping markets, many investors are looking for leaders whose incentives are tightly aligned with shareholders. Founder led companies often fit that brief, with high capital efficiency and real skin in the game that can help keep spending disciplined and focus sharp when input costs, funding and demand all feel less predictable. This article looks at three stocks from our Top Founder-Led Companies screener, giving you a...